Q3 2023 Earnings Estimate for Krystal Biotech, Inc. (NASDAQ:KRYS) Issued By HC Wainwright

Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) – Analysts at HC Wainwright upped their Q3 2023 EPS estimates for Krystal Biotech in a research note issued on Monday, May 22nd. HC Wainwright analyst J. Pantginis now expects that the company will post earnings of ($1.02) per share for the quarter, up from their previous estimate of ($1.30). The consensus estimate for Krystal Biotech’s current full-year earnings is ($5.85) per share. HC Wainwright also issued estimates for Krystal Biotech’s Q4 2023 earnings at ($0.93) EPS, FY2023 earnings at ($4.90) EPS, FY2024 earnings at ($3.10) EPS, FY2025 earnings at ($1.63) EPS, FY2026 earnings at $0.89 EPS and FY2027 earnings at $2.40 EPS.

Other equities analysts have also issued reports about the stock. William Blair reiterated an “outperform” rating on shares of Krystal Biotech in a research report on Wednesday, March 22nd. The Goldman Sachs Group upgraded shares of Krystal Biotech from a “neutral” rating to a “buy” rating and upped their price target for the stock from $79.00 to $124.00 in a research report on Tuesday, February 28th. Guggenheim upped their price target on shares of Krystal Biotech from $101.00 to $130.00 in a research report on Monday. Chardan Capital upped their price target on shares of Krystal Biotech from $133.00 to $148.00 in a research report on Monday. Finally, Stifel Nicolaus began coverage on shares of Krystal Biotech in a research report on Monday, April 17th. They issued a “buy” rating and a $102.00 price target for the company. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $126.83.

Krystal Biotech Price Performance

KRYS opened at $119.13 on Wednesday. The firm has a market cap of $3.07 billion, a P/E ratio of -22.56 and a beta of 0.85. Krystal Biotech has a 1-year low of $49.17 and a 1-year high of $123.84. The company has a 50 day simple moving average of $84.99 and a two-hundred day simple moving average of $80.50.

Krystal Biotech (NASDAQ:KRYS – Get Rating) last announced its earnings results on Monday, February 27th. The company reported ($1.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $0.01.

Insider Transactions at Krystal Biotech

In other news, CAO Kathryn Romano sold 25,000 shares of the business’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $109.04, for a total value of $2,726,000.00. Following the transaction, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,369,106.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. In related news, CAO Kathryn Romano sold 25,000 shares of the company’s stock in a transaction on Monday, May 22nd. The shares were sold at an average price of $109.04, for a total transaction of $2,726,000.00. Following the sale, the chief accounting officer now owns 12,556 shares of the company’s stock, valued at $1,369,106.24. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Dino A. Rossi sold 40,000 shares of the company’s stock in a transaction on Wednesday, March 1st. The shares were sold at an average price of $83.25, for a total transaction of $3,330,000.00. Following the sale, the director now directly owns 83,691 shares in the company, valued at approximately $6,967,275.75. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 193,428 shares of company stock valued at $17,965,513. 17.00% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Krystal Biotech

A number of hedge funds have recently bought and sold shares of KRYS. Almanack Investment Partners LLC. purchased a new stake in shares of Krystal Biotech in the third quarter valued at $52,000. Tower Research Capital LLC TRC raised its stake in shares of Krystal Biotech by 148.3% in the first quarter. Tower Research Capital LLC TRC now owns 956 shares of the company’s stock valued at $77,000 after acquiring an additional 571 shares during the period. Allspring Global Investments Holdings LLC raised its stake in shares of Krystal Biotech by 260.7% in the third quarter. Allspring Global Investments Holdings LLC now owns 981 shares of the company’s stock valued at $68,000 after acquiring an additional 709 shares during the period. Great West Life Assurance Co. Can raised its stake in shares of Krystal Biotech by 51.9% in the first quarter. Great West Life Assurance Co. Can now owns 1,013 shares of the company’s stock valued at $72,000 after acquiring an additional 346 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new stake in shares of Krystal Biotech in the first quarter valued at $104,000. Hedge funds and other institutional investors own 80.80% of the company’s stock.

Krystal Biotech Company Profile

(Get Rating)

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization.